Asimov and RevOpsis Therapeutics Ink Licensing Deal for Multispecific-Expressing Cell Line The agreement follows a cell line development campaign with Asimov’s CHO Edge System for the lead RevOpsis asset, RO-104.
Asimov and RevOpsis Therapeutics Ink Licensing Deal for Multispecific-Expressing Cell Line The agreement follows a cell line development campaign with Asimov’s CHO Edge System for the lead RevOpsis asset, RO-104.
